First Time Loading...

Cardiff Oncology Inc
NASDAQ:CRDF

Watchlist Manager
Cardiff Oncology Inc Logo
Cardiff Oncology Inc
NASDAQ:CRDF
Watchlist
Price: 3.46 USD -1.7%
Updated: May 7, 2024

Cardiff Oncology Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cardiff Oncology Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Cardiff Oncology Inc
NASDAQ:CRDF
Revenue
$488k
CAGR 3-Years
10%
CAGR 5-Years
5%
CAGR 10-Years
6%
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$29.5B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
19%

See Also

What is Cardiff Oncology Inc's Revenue?
Revenue
488k USD

Based on the financial report for Dec 31, 2023, Cardiff Oncology Inc's Revenue amounts to 488k USD.

What is Cardiff Oncology Inc's Revenue growth rate?
Revenue CAGR 10Y
6%

Over the last year, the Revenue growth was 25%. The average annual Revenue growth rates for Cardiff Oncology Inc have been 10% over the past three years , 5% over the past five years , and 6% over the past ten years .